Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

HER2-positive breast cancers can be very aggressive. For several years, the drug Herceptin has been used to treat women with HER2-positive breast cancer that has metastasized or recurred.

While the pembrolizumab copy was eye-catching, the firm’s next big biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to launch ...

If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Herceptin SC? Herceptin SC contains the active ingredient trastuzumab. Herceptin SC is used to ...

The new Herceptin formulation is now in phase 3 clinical trials, and if the program were successful, it would offer patients a convenient dosing form of the drug, which is currently given via ...

Moreover, the cells demonstrated improved growth and, compared to similarly treated controls, produced significantly higher yields of protein-based drugs such as Herceptin and Rituximab ...

This crisis has been worsened by the transition from the NHIF to the Social Health Authority (SHA), which has caused widespread disruptions in healthcare services. Be part of an exclusive group of ...

Healthcare organisations, including the Kenyan Network of Cancer Organisations (KENCO) and the NCD Alliance Kenya (NCDAK), have condemned the deteriorating health services for cancer patients, calling ...